HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
|
|
|
- Antony Dawson
- 6 years ago
- Views:
Transcription
1 drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A J8521 capecitabine (Xeloda) 1 Capecitabine, oral, 500 mg 8/1/07 $19.29 $15.21 N/A J8530 Cyclophosphamide, oral, 25 mg 9/1/06 $2.03 $0.86 N/A With each publication Managed Care Oncology s Drug & Compendia will highlight a single medication or a group of medications that could be utilized in the management of one of the featured oncology diseases. Associated ICD-9-CM s: 174 female breast Includes: breast (female), connective tissue, soft parts; Paget s disease of: breast, nipple; use additional code to identify estrogen receptor status (V86.0, V86.1) Excludes: skin of breast (172.5, 173.5) Nipple and areola Central portion Upper-inner quadrant Lower-inner quadrant Upper-outer quadrant This section will address such topics as: Associated ICD-9-CM s (includes FDA-approved 1 and Compendia approved 2 indications) Possible Medication(s) used to treat the conditions; including ancillary medication(s) Reimbursement and Coding Information (How to Bill for New Medications) Lower-outer quadrant Axillary tail Other specified sites of female breast Ectopic sites, Inner breast, Lower breast, contiguous or overlapping sites of breast whose point of origin cannot be determined, Midline of breast, Outer breast, Upper breast Breast (female), unspecified Medications currently available to treat Breast Cancer include: HCPCS/CPT codes and description Current Based Pricing Most recent ASP Plus 6% () Possible s that can be utilized with each medication 175 male breast Use additional code to identify estrogen receptor status (V86.0, V86.1) Excludes: skin of breast (172.5, 173.5) Nipple and areola Other and unspecified sites of male breast Ectopic breast tissue, male J8540 dexamethasone (Decadron) 2 Dexamethasone, oral, 0.25 mg 11/29/05 $0.11 $0.25 N/A J8610 Methotrexate, oral, 2.5 mg 9/10/03 $3.56 $0.21 N/A methotrexate 1 J9000 doxorubicin (Adriamycin) 1 J9001 doxorubicin (Doxil) 2 J9035 bevacizumab (Avastin) 1 J9045 carboplatin (Paraplatin) 2 J9060 cisplatin (Platinol) 2 J9062 cisplatin (Platinol AQ) 2 J9090 J9091 J9092 Doxorubicin, HCl, 8/7/03 $13.75 $ , 96411, 96413, Doxorubicin hydrochloride, all lipid formulations, 8/1/07 $ $ , 96411, 96413, bevacizumab, 1/1/05 $68.75 $ , 96411, 96413, Carboplatin, 50 mg 9/1/07 $54.90 $ , 96411, 96413, Cisplatin, powder or solution, per 1/1/08 $4.57 $ , 96411, 96413, Cisplatin, 50 mg 1/1/08 $22.85 $ , 96411, 96413, Cyclophosphamide, 500 mg 9/27/04 $15.80 $ , 96411, 96413, Cyclophosphamide, 1.0 gm 9/27/04 $28.45 $ , 96411, 96413, Cyclophosphamide, 2.0 gm 9/27/04 $51.20 $ , 96411, 96413, Current Price () J9170 docetaxel (Taxotere) 1 Docetaxel, 20 mg 1/1/08 $ $ , 96411, 96413, J1190 dexrazoxane HCl (Zinecard) 1 dexrazoxane hydrochloride, per 250 mg 4/28/03 $ $ , 96411, 96413, J9178 epirubicin (Ellence) 1 epirubicin HCl, 2 mg 2/1/08 $28.25 $ , 96411, 96413, J2430 pamidronate disodium (Aredia) 1 pamidronate disodium, per 30 mg 3/1/07 $ $ , 96411, 96413, J9190 fluorouracil (Adrucil) 1 Fluorouracil, 500 mg 7/1/07 $3.44 $ , 96411, 96413, 28 managedcareoncology Quarter managedcareoncology.com 29
2 Current Price () Current Price () J9201 gemcitabine (Gemzar) 1 Gemcitabine HCl, 200 mg 2/1/08 $ $ , 96411, 96413, J9370 Vincristine sulfate, 9/1/05 $10.00 $ , 96411, 96413, J9202 goserelin acetate (Zoladex) 1 J9208 ifosfamide (Ifex) 2 J9217 (Eligard, Lupron depot) 2 J9218 (Lupron) 2 J9219 (Viadur) 2 J9245 melphalan HCl (Alkeran) 2 J9250 methotrexate sodium 1 J9260 methotrexate sodium 1 J9264 paclitaxel (Abraxane) 1 J9265 paclitaxel (Taxol, Onxol) 1 Goserelin acetate implant, per 3.6 mg 1/27/00 $ $ , 96411, 96413, Ifosfamide, 1 g 7/1/07 $65.66 $ , 96411, 96413, Leuprolide acetate (for depot suspension), 7.5 mg 5/1/06 $ $ , 96411, 96413, Leuprolide acetate, per 6/1/06 $27.45 $ , 96411, 96413, Leuprolide acetate implant, 65 mg 5/18/01 $5, $1, , 96411, 96413, melphalan hydrochloride, 50 mg 2/1/07 $1, $1, , 96411, 96413, Methotrexate sodium, 5 mg 11/1/07 $0.24 $ , 96411, 96413, Methotrexate sodium, 50 mg 11/1/07 $2.38 $ , 96411, 96413, paclitaxel protein-bound particles, 2/1/08 $10.47 $ , 96411, 96413, Paclitaxel, 30 mg 2/1/08 $51.68 $ , 96411, 96413, J9375 J9380 J9390 vinorelbine (Navelbine) 2 J9395 fulvestrant (Faslodex) 1 S0156 exemestane (Aromasin) 1 S0170 anastrozole (Arimidex) 1 S0178 lomustine (CeeNu) 2 S0179 megestrol acetate (Megace) 1 S0187 tamoxifen (Nolvadex) 1 Vincristine sulfate, 2 mg 9/1/05 $20.00 $ , 96411, 96413, Vincristine sulfate, 5 mg 9/1/05 $50.00 $ , 96411, 96413, Vinorelbine tartrate, per 11/7/05 $94.00 $ , 96411, 96413, fulvestrant, 25 mg 2/1/07 $99.35 $ , 96411, 96413, Exemestane, 25 mg 2/1/08 $10.96 N/A N/A Anastrozole, oral, 2/1/07 $9.66 N/A N/A Lomustine, oral, 1/1/08 $10.31 N/A N/A Megestrol acetate, oral, 20 mg 4/1/07 $0.66 N/A N/A Tamoxifen citrate, oral, 2/20/03 $1.89 N/A N/A J9280 J9290 J9291 J9293 mitoxantrone HCl (Novantrone) 2 J9340 thiotepa 1 (Thioplex) J9355 trastuzumab (Herceptin) 1 Mitomycin, 5 mg 10/1/01 $70.00 $ , 96411, 96413, Mitomycin, 20 mg 5/1/07 $ $ , 96411, 96413, Mitomycin, 40 mg 12/1/01 $ $ , 96411, 96413, mitoxantrone hydrochloride, per 5 mg 11/1/07 $ $ , 96411, 96413, Thiotepa, 15 mg 11/1/05 $97.82 $ , 96411, 96413, Trastuzumab, 11/1/07 $72.05 $ , 96411, 96413, Additional Non-Classified Medications (These medications have not been assigned a permanent HCPCS J- by CMS) J8999: Prescription drug, oral, chemotherapeutic, Not Otherwise Specified** NDC (National Drug ) Allowable) lapatinib ditosylate /14/07 $24.17/tab $20.49/tab N/A (Tykerb), 250 mg 1 letrozole (Femara), /3/08 $11.82/tab $10.01/tab N/A 2.5 mg 1 testolactone (Teslac), /2/04 $2.66/tab $2.26/tab N/A 50 mg 1 s J9360 vinblastine 1 (Velban) Vinblastine sulfate, 12/1/01 $3.31 $ , 96411, 96413, toremifene citrate (Fareston), 60 mg , /12/07 $5.16/tab $4.38/tab N/A 30 managedcareoncology Spring Quarter managedcareoncology.com 31
3 References J8499: Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified ** NDC (National Drug ) Allowable) estradiol (Estrace), multiple 12/17/07 $1.74 $1.82 N/A 0.5 mg 1 estradiol (Estrace), multiple 12/17/07 $1.74 $1.82 N/A 1mg 1 estradiol (Estrace), multiple 12/17/07 $2.24 $1.90 N/A 2mg 1 s J9999**Not Otherwise Classified, antineoplastic drugs [Note: C9240 can be used for OPPS (Hospital Outpatient Billing), effective 1/1/08 Price is $76.83 and Ambulatory Payment Classification (APC) Rate effective 1/1/08 is $64.54] NDC (National Drug ) Allowable) - s ixabepilone (Ixempra), /17/07 $1,152.45/kit $977.28/kit 96409, 96411, 96413, 15 mg 1,, iixabepilone (Ixempra), /17/07 $3,457.36/kit $2,931.84/kit 96409, 96411, 96413, 45 mg 1,, ** When billing with a CMS 1500 claim form you must include both the HCPCS code (i.e., J8999 for Tykerb or J9999 for Ixempra) in Column 24D and the NDC (National Drug ) in Box 19 in order to ensure appropriate reimbursement. Ancillary Medications used in Cancer Treatment J2469 palonosetron (Aloxi) J1626 Q0166 S0091 J2405 ondansetron (Zofran) Q0179 ondansetron (Zofran) S0181 ondansetron (Zofran) J8501 aprepitant (Emend) palonosetron HCl, 25 mcg granisetron hydrochloride, 100 mcg Granisetron hydrochloride, 1mg oral, FDA-approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at time of chemotherapy treatment, not to exceed a 24-hour dosage regimen Granisetron hydrochloride, (for circumstances falling under the Medicare statute, use Q0166) ondansetron hydrochloride, per 1mg Ondansetron hydrochloride 8mg, oral, FDA-approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at time of chemotherapy treatment, not to exceed a 48-hour dosage regimen ( price is per 8 mg) Ondansetron HCl, oral, 4 mg (for circumstances falling under the Medicare statute, use Q0179) Current Price () 4/1/07 $39.84 $ , /1/08 $10.82 $ , /1/08 $59.01 $50.22 N/A 2/1/08 $59.01 N/A N/A 12/1/07 $0.75 $ /1/07 $39.36 $9.17 N/A 1/1/08 $23.98 N/A N/A Aprepitant, oral, 5 mg 9/1/07 $6.60 $5.23 N/A HCPCS Level II Expert Current Procedural Terminology (CPT) ICD-9-CM for Professional Volumes 1 & The Drug Reimbursement Coding and Pricing Guide by R J Health Systems International, LLC Volume 5, Number 1, 1st Quarter Oncology Related HCPCS s This reference chart will assist the Oncology Office (Office Manager, Oncology Nurse, Physician and Ancillary Staff) and payor with the appropriate codes to utilize when billing or reimbursing for medication(s) J0881 darbepoetin alfa (Aranesp) J0885 epoetin alfa (Procrit, Epogen) J0894 decitabine (Dacogen) J1440 (300 mcg) (Neupogen) darbepoetin alfa, 1 microgram (non-esrd use) epoetin alfa, (for non- ESRD use), 1000 units decitabine, (G-CSF), 300 mcg Anemia in chronic kidney disease (285.21) Anemia in neoplastic disease (285.22) Anemia, unspecified (285.9) Anemia in chronic kidney disease (285.21) Anemia in neoplastic disease (285.22) Anemia, unspecified (285.9), Other decreased white blood cell count (288.59) Convalescence and palliative care- Following chemotherapy (V66.2) 1 FDA-approved indication (Product prescribing information) 2 Compendia approved indication (Drug Points by Thomson Micromedex) powered by R J Health Systems International LLC Price**/ N/A $5.79 Anemia of other chronic disease (285.29), Other lymphatic and hematopoietic tissues (238.79) (205.0) Myeloid leukemia (205._) Monocytic leukemia (206._) Other specified leukemia (207._) Leukemia of unspecified cell type-acute (208.0_), Other lymphatic and hematopoietic tissues (238.79) $15.16 $ /1/2007 $ CMS (Centers for Medicare and Medicaid Services) 1st Quarter s 1/1/08-3/31/08 The information contained was supplied by R J Health Systems International LLC located in Wethersfield, Connecticut. Prices listed herein are effective as of February 25, $ $ $ $ managedcareoncology Spring Quarter managedcareoncology.com 33
4 Price**/ Price**/ J1441 (480 mcg) (Neupogen) J1645 dalteparin sodium (Fragmin) J2505 peg (Neulasta) (G-CSF), 480 mcg dalteparin sodium, per 2,500 IU eg, 6 mg Other decreased white blood cell count (288.59) Convalescence and palliative care- Following chemotherapy (V66.2) Acute myocardial infarction (410._) Intermediate coronary syndrome (411.1) Phlebitis and thrombophlebitis-of deep vessels of lower extremities (451.1_) Phlebitis and thrombophlebitis Of deep veins of upper extremities (451.83) of lower extremity (453.4_) of lower extremity Of other specified veins (453.8) of lower extremity Of unspecified site (453.9) Other decreased white blood cell count (288.59) Myeloid leukemia (205._) Monocytic leukemia (206._) Other specified leukemia (207._) Leukemia of unspecified cell type-acute (208.0_), Other lymphatic and hematopoietic tissues (238.79) $ N/A $21.37 N/A $3, $ $ $2, J3315 triptorelin pamoate (Trelstar Depot, Trelstar LA) J3487 zoledronic acid (Zometa) J9025 azacitidine (Vidaza) J9041 bortezomib (Velcade) J9050 carmustine (BiCNU) J9055 cetuximab (Erbitux) triptorelin pamoate, 3.75 mg zoledronic acid (Zometa), azacitidine, bortezomib, 0. Carmustine, 100 mg cetuximab, prostate (185) Hypercalcemia (275.42) Bone and bone marrow (198.5), Other lymphomas (Mantle Cell Lymphoma) (202.80) brain (191._) Hodgkin s disease (201. ) reticulosarcoma and other specified malignant tumors of lymphatic tissue (200. ) colon lip (140._) tongue (141._) major salivary glands (142._) gum (143._) floor of mouth (144._) other and unspecified parts of mouth (145._) oropharynx (146._) nasopharynx (147._) hypopharynx (148._) other and ill-defined sites within the lip, oral cavity, and pharynx (149._) nasal cavities, middle ear, and accessory sinuses (160._) larynx (161._) Head, face, and neck (195.0) N/A $ /17/2005 Disorder of bone and cartilage, unspecified (733.90) (205.0) $ $5.26 5/1/2007 $42.57 colon Other lymphomas (202.8_) Malignant melanoma of skin (172._) Malignant neoplasm of stomach (151._) pancreas (157._) $ /1/2008 $ /1/2005 $ $ $ $ $ $ managedcareoncology Spring Quarter managedcareoncology.com 35
5 J9065 cladribine (Leustatin) J9120 dactinomycin (Cosmegen) J9150 daunorubicin (Cerubidine) cladribine, per Dactinomycin, 0.5 mg Daunorubicin, Leukemic reticuloendotheliosis (202.4_) bone and articular cartilage (170._) connective and other soft tissue (171._) testis (186._) Other and unspecified testis (186.9) placenta (181) Neoplasm of uncertain behavior of genitourinary organs Placenta (236.1) unspecified urinary organs- Kidney, except pelvis (189.0) Lymphoid leukemia Acute (205.0_) Lymphoid leukemia Chronic (204.1_) Mycosis fungoides (202.1_) Sezary s disease (202.2_) Other lymphomas (202.8_) reticulosarcoma and other specified malignant tumors of lymphatic tissue (200. ) Nodular lymphoma (202.0_) Malignant histiocytosis (202.3_) Letterer-Siwe disease (202.5_) Malignant mast cell tumors (202.6_) Peripheral T-cell lymphoma (202.7_) Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue (202.9_) Lymphoid leukemia acute Kaposi s sarcoma (176._) Secondary malignant neoplasm of other specified sites Bone and bone marrow (198.5) ovary (183._) bone and articular cartilage (170._) nasal cavities, middle ear, and accessory sinuses (160._) other endocrine glands and related structures - Adrenal gland (194.0) reticulosarcoma and other specified malignant tumors of lymphatic tissue (200. ) unspecified urinary organs Kidney, except pelvis (189.0) Myeloid leukemia Chronic (205.1_) Price**/ $ /30/2004 $ /24/2006 $ /1/2001 $ $ $ J9200 floxuridine (FUDR) J9206 irinotecan hydrochloride (Camptosar) J9211 idarubicin (Idamycin) J9225 histerlin implant (Vantas) J9263 oxaliplatin (Eloxatin) J9266 pegaspargase (Oncaspar) J9303 panitumumab (Vectibix) J9305 pemetrexed disodium (Alimta) J9310 rituximab (Rituxan) Floxuridine, 500 mg Irinotecan, 20 mg Idarubicin hydrochloride, 5 mg Histrelin implant (Vantas), 50 mg oxaliplatin, 0.5 mg Pegaspargase, per single dose vial panitumumab, pemetrexed, Rituximab, 100 mg Oncology Related J- References HCPCS Level II Expert Current Procedural Terminology (CPT) The Association of Community Cancer Centers Compendia-Based Drug Bulletin August DrugPoints by Thomson Micromedex 2008 liver and intrahepatic bile ducts (155._) colon (205.0_) prostate (185) colon Lymphoid leukemia-acute colon trachea, bronchus, and lung (162._) pleura (163._) reticulosarcoma (200. ) Rheumatoid arthritis and other inflammatory polyarthropathies (714._) colon unspecified urinary organs Kidney, except pelvis (189.0) unspecified urinary organs Renal pelvis (189.1) ovary Ovary (183.0) stomach (151._) cervix uteri (180._) trachea, bronchus, and lung (162._) ovary (183._) Lymphoid leukemia Acute Price**/ $ $ /27/2004 $ /1/2007 N/A $6, stomach (151._) $ /1/2008 N/A $3, trachea, bronchus, and lung (162._) female breast (174._) male breast (175._) Lymphoid leukemia-chronic (204.1_) Immune thrombocytopenic purpura (287.31) Disorders of plasma protein metabolism- $ /1/2007 $57.43 $ $ $ $ $1, $ $2, $ $ $ **The Price is based on the HCPCS. HCPCS (Healthcare Common Procedure Coding System) codes are a component of CMS (Centers for Medicare and Medicaid Services). The Price is an based pricing methodology developed by R J Health Systems International, LLC., Wethersfield, CT American Medical Association. Professional ICD-9-CM 2008 Volumes 1 and 2. AMA Press, Full prescribing information for each drug listed. The Drug Reimbursement Coding and Pricing Guide by R J Health Systems International, LLC Volume 5, Number 1, 1st Quarter powered by R J Health Systems International, LLC CMS (Centers for Medicare and Medicaid Services) 1st Quarter s 1/1/08-3/31/08 36 managedcareoncology Spring Quarter managedcareoncology.com 37
Medications currently available to treat Multiple Myeloma include: Current Code Price (AWP) Effective Date. Code Price (AWP)
drug and administration compendia Compendia information developed and maintained by With each publication Managed Care Oncology s Drug & Compendia will highlight a single medication or a group of medications
Ovarian Cancer. compendia TREATMENT OF
drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management
Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration
Drug & Administration compendia Treatment of Melanoma With each publication, ManagedCare Oncology s Drug & Administration Compendia highlights a single medication or a group of medications that could be
Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com
Drug & compendia Treatment of Leukemia With each publication, Managed Care Oncology s Drug & Compendia highlights a single medication or a group of medications that could be utilized in the management
To help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
Compendia information developed and maintained by. In each issue, Managed Care. Oncology s Drug & Administration. Compendia will highlight a single
drug and administration compendia Compendia information developed and maintained by In each issue, Managed Care Oncology s Drug & Compendia will highlight a single medication or a group of medications
Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
Chemotherapy 101 for Radiation Oncology Workers
Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent
Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abraxane) Reference Number: CP.PHAR.176 Effective Date: 07.01.15 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
Subject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
Committee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
Cancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
Subject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
Cancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on ICD-10 Coding of Neoplasms Introduction The International Statistical Classification of Diseases and Related Health Problems, 10 th Revision (ICD-10)
Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
Guideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
Bladder Cancer Pathways (Urothelial)
Bladder Cancer Pathways (Urothelial) Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op
Part B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
Part B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
ANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
Adjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
Breast Health. Cancer Online Patient Education Library. General Education. Breast Imaging Procedures. Breast Anatomy Graphics
Breast Health General Education Antiperspirants and Breast Cancer 0101 Bra Fitting 0102 Breast Cancer Facts 0103 Breast Cancer Misconceptions 0104 Breast Cancer Statistics 0105 Breast Self-Exam 0106 Caffeine
Bladder Cancer (Urothelial) Pathways
Bladder Cancer (Urothelial) Pathways Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op
Haematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
Introduction to Antineoplastic Prescribing
Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand
Objectives. Principles of Cancer Treatment. Cancer Treatment Modalities. Cancer Treatment Modalities
Objectives Principles of Cancer Treatment Juanita Madison, RN, MN, AOCN Oncology Clinical Nurse Specialist Seattle Cancer Care Alliance Describe the principles of cancer treatment Surgery Chemotherapy
Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17
Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
MASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Alimta) Reference Number: CP.PHAR.368 Effective Date: 10.31.17 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
UNDERWRITING GUIDE. Secure Advantage HOSPITAL COVERAGE. The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization
UNDERWRITING GUIDE Secure Advantage HOSPITAL COVERAGE The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization TABLE OF CONTENTS Contents Page Secure Advantage Underwriting Guide...2
The following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
UP Health System Marquette Medication Guideline High Alert Drugs
1 ALTEPLASE SOLR 100 MG ACTIVASE 305010 50242008527 TRUE ALTEPLASE SOLR 50 MG ACTIVASE 305008 50242004413 TRUE AMIODARONE INJ 50 MG/ML CORDARONE IV 305035 63323061609 TRUE AMIODARONE INJ 50 MG/ML CORDARONE
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous
Breast Cancer Patients: Begin on page 1, then skip to page 3 Lymphoma Patients: Begin on page 2 1. Newly diagnosed with Breast carcinoma Stage: (includes inflammatory breast and newly diagnosed recurrent
CLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
Standard Breast Cancer Therapy
Pt s Who Don t Follow Treatment Standard Breast Cancer Therapy Deborah Thames R.T. (R)(M)(QM) Advancements in Breast Cancer Advancements in Breast Cancer Chemotherapy Full potential was recognized in the
DATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY
Date: 10 th April 2018 DATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY Request: 1. Utilization Data of Overseas Beam Therapy and Brachytherapy 2. Diagnoses Data of Overseas Claims for Beam Therapy and Brachytherapy
APPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
Guidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]
![INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]](/thumbs/85/92112268.jpg "INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]")
Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of
TRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
Medicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
CPT Service Description Effective Date
Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,
DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
EquiCash UNDERWRITING GUIDE. Equitable &You. The Policy That Pays You Cash In The Event You Have To Be Hospitalized HOSPITAL PLAN
UNDERWRITING GUIDE EquiCash HOSPITAL PLAN The Policy That Pays You Cash In The Event You Have To Be Hospitalized Rev. 10/13 Equitable &You... Committed To Caring TABLE OF CONTENTS Contents Page EquiCash
Hazard Meds: Navigating the Warning Beacons
Hazard Meds: Navigating the Warning Beacons Disclosures I have nothing to disclose at this time. Mark Twohey, Pharm.D., BCOP Palmetto Health Richland March 24, 2012 Objectives Understand the reasons for
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
Annual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.
Annual Report Cape Cod Hospital and Falmouth Hospital Regional Cancer Network 2013 Expert physicians. Quality hospitals. Superior care. Cape Cod Hospital s Davenport- Mugar Hematology/Oncology Center and
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
LCD for Interferon (L29202)
LCD for Interferon (L29202) Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B Contractor Information LCD ID Number L29202 LCD Information LCD Title
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
CLINICAL MEDICATION POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICATION POLICY Granulocyte Colony Stimulating Factors (G-CSFs) MP-016-MD-DE Medical Management; Clinical Pharmacy Provider Notice Date:
Infusion Coding. Is this going to hurt? Presented by: Annalynn Hall, M.Ed, CPC, CHONC. Codes
Infusion Coding Is this going to hurt? Presented by: Annalynn Hall, M.Ed, CPC, CHONC 1 Codes The codes used in this presentation are copyrighted by the AMA Review all codes and code descriptions for appropriate
Empowering Patients To COPE One Topic at a Time. Breast Health Edition
Empowering Patients To COPE One Topic at a Time Breast Health Edition 427 Breast Health Topics The new helps you educate your patients. Easily provide each patient with information that answers their questions
2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
Latest News in Breast Cancer Research
Latest News in Breast Cancer Research Highlights from the 2011 San Antonio Breast Cancer Symposium www.cancercare.org This special edition of the CancerCare Connect booklet series highlights cutting-edge
Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
CLINICAL MEDICATION POLICY
CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals
1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
The effect of new cancer drug approvals on the life expectancy of American cancer patients,
Economics of Innovation and New Technology Vol. 18, No. 5, July 2009, 407 428 The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978 2004 Frank R. Lichtenberg*
Drug Use Evaluation: Physician Administered Drugs (PADs)
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Drug Use Evaluation: Physician Administered
NEW/REVISED MATERIAL: Presented in italicized text EFFECTIVE DATE: January 1, 2008 GUIDELINES FOR REPORTING ADMINISTRATION OF EPOGEN MEDICARE
DISCLAIMER: Please be advised that while every effort has been made to ensure the accuracy of the information provided according to the most current LCD pertaining to the subject, periodic change to rules
Colony Stimulating Factors: Neupogen (filgrastim), Neulasta (pegfilgrastim), Leukine (sargramostim), Granix (tbo-filgrastim)
Neupogen (filgrastim), Neulasta (sargramostim), Granix (tbo-filgrastim) Date of Origin: 10/17/2008 Dates Reviewed: 6/17/2009, 12/22/2009, 06/15/2010/ 7/20/2010, 09/2010, 12/2010, 03/2011, 06/2011, 09/2011,
ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
Eloxatin (Oxaliplatin)
Policy Number ELO12012011RP Approved By UnitedHealthcare Medicare Committee Current Approval Date 09/10/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
The Community Oncologist
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com The Community Oncologist Preventing Chemotherapy Errors Lisa
SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
TRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths
RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected
Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
MEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
Introduction to ICD-O-3 coding rules
Introduction to ICD-O-3 coding rules Weena Laddachayaporn, MD National Cancer Institute, Bangkok, Thailand ICD-O-3 The International Classification of Diseases for Oncology Is a coding system for primary
Coding Tips, Hints & Pointers for Medical Oncology Billing
Coding Tips, Hints & Pointers for Medical Oncology Billing Empire State Hematology & Oncology Society Meeting October 5, 2018 Disclaimer When a third party payer is involved, the determination of reimbursement
REGULATORY INFORMATION
REGULATORY*INFORMATION/*CANCER*MEDICINES* Summary'of'regulatory'status'of'the'medicines' As#recommended#in#the#EML#Secretariat s#instructions#regarding#applications#for#the#addition#of#new# medicines#
Managements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer